Latest / Pharmacy Podcast Network / ATRIUMX Pharmacy Conference and the Truth about GLP-1 Drugs | TWIRx
Transcript
- 0:06Speaker 1: Hey, this is Scott and Tamra from the LTC Pharmacy Podcast.
- 0:09Speaker 1: We just wanted to take a minute to give a
- 0:11Speaker 1: shout out to the Pharmacy podcast Network.
- 0:14Speaker 2: Guys.
- 0:14Speaker 3: The Pharmacy podcast Network is amazing.
- 0:16Speaker 4: It has given a voice to pharmacists across the nation
- 0:20Speaker 4: in each of their respective niches.
- 0:22Speaker 5: The niches, niche, niche.
- 0:25Speaker 2: Whatever it is. It's given us all of the noise
- 0:28Speaker 2: and we have loved every second of it.
- 0:30Speaker 1: It's been great to be uplifted by the Pharmacy Podcast
- 0:33Speaker 1: Network knowing that we are all in this together, supporting
- 0:35Speaker 1: one another and making each other better. So thank you
- 0:38Speaker 1: Pharmacy Podcast Network for all you do and don't forget.
- 0:41Speaker 3: To tune in to the LTC Pharmacy Podcast.
- 0:47Speaker 2: Hi.
- 0:48Speaker 6: I'm Conelvius, co founder and CEO of RX Mile. Are
- 0:52Speaker 6: you ready to take your pharmacy business to the next level?
- 0:55Speaker 6: Join me on the exciting journey as I sit down
- 0:58Speaker 6: with Todd Uriy from the Pharmacy podct Cast Network. In
- 1:00Speaker 6: our special episodes The Last Mile with rx Mile, we'll
- 1:05Speaker 6: be diving into how ourx mile is revolutionizing the way
- 1:08Speaker 6: pharmacies operate, from enhancing patient adherence to streamlining delivery services,
- 1:14Speaker 6: learn about our cutting edge solution that is transforming our industry,
- 1:18Speaker 6: and hear success stories from pharmacy owners just like you.
- 1:22Speaker 6: Don't miss out on this chance to stay ahead of
- 1:24Speaker 6: the curve. Tune into the Last Mile with RX Mile,
- 1:29Speaker 6: available on all major platforms. Subscribe now and elevate your
- 1:33Speaker 6: pharmacy with us.
- 1:35Speaker 7: See you there, hey, on this weekend Pharmacy our special feature.
- 1:40Speaker 7: If you were a if you were listening over the
- 1:44Speaker 7: last couple of weeks, we've been talking about Atrium X.
- 1:48Speaker 7: This is a conference that is different than any conference
- 1:52Speaker 7: I've ever been to. This is why I'm so pumped
- 1:54Speaker 7: up about this, where we have pharmacist business expertise, pharmacy owners,
- 2:01Speaker 7: technologists coming together to decide on the fly, hey, what's
- 2:08Speaker 7: the most important and pressing things to be talking about
- 2:11Speaker 7: for the thrive ability and the surviving of our community pharmacies.
- 2:16Speaker 7: Because I don't have to tell you you're listening, if
- 2:18Speaker 7: you're in the car, you're driving, you might not be
- 2:20Speaker 7: watching us on YouTube or live on LinkedIn, which is fine.
- 2:24Speaker 7: You are probably stressed out in some ways about our
- 2:28Speaker 7: pharmacy profession. It's going through massive, massive upheaval and changing
- 2:33Speaker 7: the way that pharmacist is paid provider status. You know,
- 2:39Speaker 7: technology upgrades, artificial intelligence. That we're not coming to this
- 2:45Speaker 7: conference to worry. We're coming to this converts to strategize
- 2:49Speaker 7: and execute. And that's what I'm most excited about, because
- 2:53Speaker 7: I want to be in the middle of an organization
- 2:56Speaker 7: and a conference, surrounded by people who understand where we
- 3:00Speaker 7: have been, where's pharmacy been twenty years ago, right where
- 3:05Speaker 7: we are today, where we're going, and what we need
- 3:07Speaker 7: to do. And with that, I'd like to welcome my
- 3:12Speaker 7: four guests and saying hello. First, starting out with Nicolette Matthew.
- 3:17Speaker 7: Doctor Matthew is the founder of a trim X. It's
- 3:20Speaker 7: great to have you back on twerks and I'm not
- 3:23Speaker 7: going to make you trks again, but I'll.
- 3:24Speaker 3: Do some twerksing like this. I can't do it on
- 3:28Speaker 3: a chair, but Nicole, welcome back.
- 3:30Speaker 5: Yeah, thank you so much, Todd, thanks for having us today.
- 3:34Speaker 7: All right, and then I'd like to welcome pharmacy owner
- 3:37Speaker 7: Donnie Jordan.
- 3:39Speaker 3: Welcome to Turks. This is the first time on twerks.
- 3:42Speaker 3: Thanks Tod, thanks for having me.
- 3:43Speaker 4: I've got a great group with me today and I'm
- 3:45Speaker 4: excited to participate with these guys.
- 3:48Speaker 7: Kelly, you are one of my heroes in pharmacy as
- 3:51Speaker 7: a speaker. I've been watching you since PDS days. I
- 3:57Speaker 7: just you're one of the warmest people in the pharmacy profession.
- 4:01Speaker 3: Thanks for being here.
- 4:02Speaker 5: Thank you, Todd.
- 4:03Speaker 8: It is such an honor or privilege, and I just
- 4:05Speaker 8: love the innovative things that Nicola's doing here.
- 4:09Speaker 7: Absolutely another Jedi master of the pharmacy industry.
- 4:13Speaker 3: Jennifer Dale, Welcome to twerks.
- 4:16Speaker 9: Thank you so much for having me, tad excited to
- 4:18Speaker 9: be here.
- 4:19Speaker 7: All right, throwing Nicolette back into the hot seat. For
- 4:23Speaker 7: our listeners out there, tell us you know, you and
- 4:27Speaker 7: I have been talking about this.
- 4:28Speaker 3: This is your third time on twerks. We've been talking
- 4:30Speaker 3: about this. We want to know, you know, what's.
- 4:33Speaker 7: Different about this conference for people that might not have
- 4:35Speaker 7: listened to the late latest episodes. And then this is
- 4:38Speaker 7: a two part question. And second, how are we going
- 4:40Speaker 7: to come up with the subjects? Like what are what
- 4:42Speaker 7: are what are the subjects?
- 4:43Speaker 3: What are they going to be? How are we going
- 4:44Speaker 3: to determine that?
- 4:45Speaker 10: Yeah, great question, and it's it's so exciting this conference.
- 4:50Speaker 10: It's it's something that we need in the industry. So
- 4:53Speaker 10: many pharmacy owners that I talk with on a daily basis, like,
- 4:56Speaker 10: we're all coming into the new year. We're seeing what's
- 4:59Speaker 10: happened with reimbursements, We're seeing what's happening with the change.
- 5:02Speaker 10: We have a new administration that just came into place,
- 5:05Speaker 10: and now everybody's like, Okay, we're over the holidays, we're
- 5:09Speaker 10: into the new year.
- 5:10Speaker 5: We have a little grasp on what's going on.
- 5:11Speaker 10: What's our strategy for this year, what are the things
- 5:14Speaker 10: that are keeping us up at night, and how are
- 5:16Speaker 10: we going to work through them so that we can
- 5:18Speaker 10: continue to serve our employees and our patients and our
- 5:22Speaker 10: communities and our prescribers. So with our conference with Atrium X,
- 5:27Speaker 10: and it's coming up very soon, it's just a couple
- 5:29Speaker 10: of weeks away, the inaugural first year conference of Atrium X,
- 5:34Speaker 10: we have so many bright minds already committed to coming
- 5:39Speaker 10: and we want to invite you to join as well,
- 5:41Speaker 10: if anybody's listening kind of on the fence, but really
- 5:45Speaker 10: it's just innovation. So we're getting all these bright minds
- 5:48Speaker 10: together and we have these expert facilitators on the call
- 5:52Speaker 10: as well, and we do breakout sessions and we actually
- 5:55Speaker 10: do voting and polling and physical voting. And it's not
- 5:59Speaker 10: a huge it's intimate, so you're going to really get
- 6:03Speaker 10: to know the folks who are there. You're going to
- 6:05Speaker 10: get to know do they focus on you know, long
- 6:08Speaker 10: term care at home billing, do they focus on you know,
- 6:12Speaker 10: medicare plan enrollments, do they focus on compounding? Are they
- 6:17Speaker 10: getting into five O three b's and glps? And everybody
- 6:20Speaker 10: will be voting what do they want to talk about?
- 6:22Speaker 10: Maybe it's employee engagement something like that. And then we
- 6:26Speaker 10: actually this structure has been around for some time in
- 6:30Speaker 10: other industries, so we're like, we're doing a brand new conference,
- 6:33Speaker 10: why don't we put a brand new format in there too,
- 6:36Speaker 10: and pull together some of the smartest people we know.
- 6:38Speaker 5: And most passionate innovative people. And so we did.
- 6:41Speaker 10: And so this has been happening in Silicon Valley, It's
- 6:44Speaker 10: been happening in other industries, but never in the independent
- 6:48Speaker 10: pharmacy industry. And truthfully, Todd, to your point, we're all
- 6:52Speaker 10: struggling and we need this innovation. We need to kind
- 6:56Speaker 10: of break the mold on how we strategize in the
- 6:59Speaker 10: new year, and that's what we're going to do at Atreuemex.
- 7:02Speaker 3: That's awesome.
- 7:03Speaker 7: Yeah, Kelly, you're one of the first people that I
- 7:06Speaker 7: thought of when Marie told me about this, and I
- 7:09Speaker 7: got an opportunity to talk with Nicolette before her first
- 7:11Speaker 7: showing on TWERS. You get this kind of stuff because
- 7:16Speaker 7: you've always been thinking ahead of things, So tell us
- 7:19Speaker 7: you are kind of perception of what we're bringing together.
- 7:23Speaker 8: Well, first of all, let me say that my business
- 7:26Speaker 8: partner Terry norvel and I are thrilled to join jin
- 7:29Speaker 8: as the facilitators for this event and being able to
- 7:35Speaker 8: curate the most important pharmacy topics for discussion and dialogue
- 7:40Speaker 8: and the emergency of best practices. My business partner, Terry
- 7:44Speaker 8: Norvelle is actually she would be on the call today,
- 7:47Speaker 8: but she's out sharpening the saw. She is actually at
- 7:50Speaker 8: a week long workshop herself in Santa Fe, and of
- 7:54Speaker 8: course she sends her love and her best to everyone.
- 7:56Speaker 5: So yes, this.
- 7:58Speaker 11: Is I think the most unique way to not only
- 8:04Speaker 11: present insight and topics and content that really resonate and
- 8:11Speaker 11: are completely relevant to the attendee.
- 8:14Speaker 3: Right, there's no.
- 8:15Speaker 5: Access, there's no excess is fat.
- 8:17Speaker 8: Right, or it's all meat, and it's sort of the
- 8:21Speaker 8: meat and potatoes of the meal. And not only will
- 8:26Speaker 8: we be able to explore in depth, will be able
- 8:30Speaker 8: to create action plans like concrete steps, maybe a checklist,
- 8:36Speaker 8: if you will, for owners and their teams to be
- 8:39Speaker 8: able to actually get some of these projects, some of
- 8:43Speaker 8: these initiatives that.
- 8:44Speaker 5: Will really impact not just the people. You know, I
- 8:48Speaker 5: think of people in really in three ways. Right, It's
- 8:52Speaker 5: the it's.
- 8:52Speaker 8: The the employee themselves, right, It's the team, it's the patient.
- 8:59Speaker 8: And so when you think about people and process which
- 9:04Speaker 8: leads to profit, you have to be able to get
- 9:07Speaker 8: these initiatives across the finish line.
- 9:11Speaker 5: So I think it's twofold.
- 9:13Speaker 8: It's the emergence of the topics that matter most, and
- 9:17Speaker 8: then it's helping them to craft that roadmap to get
- 9:23Speaker 8: it implemented. And you know, that's where I think I'm
- 9:26Speaker 8: going to include you, Jen, and this as well, is
- 9:29Speaker 8: that the three of us as facilitators are if nothing else,
- 9:32Speaker 8: we're pragmatic about what is happening in pharmacy. We're intimate
- 9:38Speaker 8: with the challenges and the pain points. We sort of
- 9:41Speaker 8: hack into your lives for a living, so we understand
- 9:46Speaker 8: the nature of the beast and can uniquely.
- 9:50Speaker 5: Assist and support.
- 9:52Speaker 8: With the creation of an action plan that makes sense
- 9:56Speaker 8: because of the intimacy and the size of the group.
- 10:00Speaker 3: So cool. I want Kelly Jen to extend on that.
- 10:03Speaker 5: Yeah, thank you.
- 10:05Speaker 9: I was thinking I just wanted to extend what you
- 10:07Speaker 9: were talking about, Kelly. The first thing is is that
- 10:10Speaker 9: we know that many of these pharmacies are suffering or
- 10:13Speaker 9: experiencing or have the same opportunities across the board, right,
- 10:17Speaker 9: and to be able to this is an excellent opportunity
- 10:20Speaker 9: to be able to get them together and they're not
- 10:22Speaker 9: getting an agenda ahead of time. They get to co
- 10:25Speaker 9: create the agenda so they know they're actually working on
- 10:28Speaker 9: the meat, as you said, Kelly, and we know that
- 10:31Speaker 9: they all get to get together and work on the
- 10:33Speaker 9: same opportunities that everybody is experiencing across the country.
- 10:37Speaker 3: Sure, excellent.
- 10:38Speaker 7: You know the person that matters most to me and
- 10:41Speaker 7: the mixture of the cookie is the pharmacy owner. Done
- 10:45Speaker 7: when you think about this mastermind strategy coming together business
- 10:50Speaker 7: minds who don't understand what's going on and technology, because
- 10:54Speaker 7: there's going to be a bunch of vendors there that
- 10:56Speaker 7: are all focused on technology. What's your impression of this
- 10:59Speaker 7: conference as a pharmacy owner.
- 11:01Speaker 4: I'm super excited about it for a multitude of reasons.
- 11:05Speaker 4: I think one is the fact that a lot of
- 11:08Speaker 4: these shows that I've gone to throughout my career, whether
- 11:11Speaker 4: that's been chain shows, pharmacists specific shows, industry shows, wholesaler shows.
- 11:19Speaker 4: A lot of times I sit around and I look
- 11:21Speaker 4: at a lot of the content and I think, who
- 11:23Speaker 4: created this?
- 11:24Speaker 2: Is this even relevant anymore? Right?
- 11:27Speaker 4: And knowing that we get to go in and talk
- 11:31Speaker 4: about what's important to us in the industry today, that
- 11:36Speaker 4: is super exciting. I think the other thing that really
- 11:39Speaker 4: gets me pumped up is listen, it's still early twenty
- 11:42Speaker 4: twenty five.
- 11:44Speaker 2: We've got the ability to go ahead.
- 11:45Speaker 4: And plan our objectives for the whole year and learn
- 11:50Speaker 4: what it is that we want to implement and go
- 11:54Speaker 4: do it right and get that plan. And at the
- 11:56Speaker 4: end of the day, being able to sit in a
- 11:58Speaker 4: room with other pharmacy the owners and other pharmacy experts
- 12:02Speaker 4: who have already done some things is really exciting. There's
- 12:07Speaker 4: some things around long term care at home that I
- 12:09Speaker 4: can't wait to share. While I'm there with everybody of
- 12:12Speaker 4: the success that's been had, and there are other things
- 12:15Speaker 4: I can't wait to talk about, like how in the
- 12:17Speaker 4: world are we going to address the Inflation Reduction Act
- 12:21Speaker 4: that's coming in twenty twenty six and start to have
- 12:24Speaker 4: those conversations and what this feels like to me. Nicolette
- 12:28Speaker 4: and I have talked about this a little.
- 12:29Speaker 2: Bit, is.
- 12:31Speaker 4: So many of the great experiences I've had at conferences
- 12:35Speaker 4: has been in the hallways at the hotel bar and
- 12:40Speaker 4: just kind of casual conversations that are a listening, real
- 12:44Speaker 4: response around what really works practically. You know, Kelly mentioned
- 12:49Speaker 4: being pragmatic and how you approach it. This is real
- 12:54Speaker 4: life stuff that we know can work, and somebody can
- 12:57Speaker 4: help give you the shortcut of the things that they've
- 12:59Speaker 4: learned along the way, and that's what's really.
- 13:02Speaker 5: Exciting to me. That's exactly right, Donnie.
- 13:05Speaker 10: And I'm most excited about that part too, because even
- 13:09Speaker 10: at Atrium twenty four here and we have our dot
- 13:12Speaker 10: ACRM software, So we started off consulting five plus years
- 13:16Speaker 10: ago and now we're strictly a software company for that
- 13:20Speaker 10: and we curate webinars like twice a month. So I'm
- 13:23Speaker 10: always talking to pharmacy owners and I'm like, tell.
- 13:25Speaker 5: Me more about that. I'm like, what did you try.
- 13:27Speaker 10: How did it work, how would you do it differently
- 13:29Speaker 10: next time? What companies did you work with? How much
- 13:31Speaker 10: did you pay? How did you track your metrics? You know,
- 13:34Speaker 10: And I'm like asking a million questions. But then all
- 13:36Speaker 10: that information that I gather, I then give it to
- 13:39Speaker 10: other pharmacy owners.
- 13:40Speaker 5: So that the give me more information.
- 13:42Speaker 10: And so I'm most excited, you know, seeing all the
- 13:45Speaker 10: names of all the folks who have registered for the
- 13:47Speaker 10: conference already.
- 13:49Speaker 5: And I'm like, oh, I can't believe.
- 13:50Speaker 10: You know, Mac Superman, pharmacist from Master Immunizer from Pennsylvania
- 13:56Speaker 10: is going to be there, and Justin Clark from Velveston, Arizona,
- 13:59Speaker 10: and Nick and Sandra New Sterile Compounders.
- 14:02Speaker 5: They've been sterile compounding for a year out of Texas.
- 14:04Speaker 10: I'm like, I can't wait to put this person with
- 14:06Speaker 10: that person with this and just sit back and listen
- 14:09Speaker 10: because I'm going to learn so much.
- 14:11Speaker 5: So it's just such a cool environment that I'm just
- 14:14Speaker 5: I'm so excited to be sitting in.
- 14:16Speaker 10: That room in two weeks with all these just the
- 14:20Speaker 10: most innovative minds in our industry.
- 14:23Speaker 7: Absolutely, Yeah, absolutely, And I like the thought that it's
- 14:28Speaker 7: a smaller environment, a smaller conference because back to what
- 14:32Speaker 7: Donnie was saying, to have conversations with people that can
- 14:36Speaker 7: go from two people to four people, to eight people
- 14:39Speaker 7: to sixteen people all sitting at a table, that is
- 14:43Speaker 7: so cool. Because Donnie knows things as a pharmacy owner
- 14:47Speaker 7: and a pharmacy consultant of the business of pharmacy. He
- 14:51Speaker 7: injects in some of the I feel like we're making
- 14:53Speaker 7: a big pot of chili. It's going to be out
- 14:56Speaker 7: there and we're all putting in the ingredients and we're
- 14:59Speaker 7: constantly making pivots and adjustments and a lot of creativity
- 15:04Speaker 7: in the groups too.
- 15:06Speaker 10: Yeah, even the connections that we're going to make. I
- 15:09Speaker 10: love to just save everybody's contact information on my phone,
- 15:12Speaker 10: get their emails, and then you know it is. You
- 15:15Speaker 10: might think of something three months down the road and
- 15:16Speaker 10: be like, oh, you know who can help me with that?
- 15:18Speaker 10: You know, or you know who said they were doing that,
- 15:21Speaker 10: and then you ping them. Don't connect you with someone else.
- 15:24Speaker 10: So if you want to change, you know what you're doing,
- 15:29Speaker 10: you have to do something differently. You have to get
- 15:32Speaker 10: outside of your bubble, you have to jump into new experiences,
- 15:37Speaker 10: and so this is what this is what we're going to.
- 15:39Speaker 3: Do, Nicole.
- 15:42Speaker 9: I was just thinking about what you were just saying.
- 15:44Speaker 9: How you pick a pharmacy and you say you're doing this, Okay,
- 15:47Speaker 9: let me share this with someone else. And I do
- 15:50Speaker 9: the same thing, and I'm sure Kelly's doing the same thing,
- 15:52Speaker 9: and Donnie's doing the same thing. And we're only individuals.
- 15:54Speaker 9: So if you can imagine the magnitude of putting us
- 15:57Speaker 9: all together and getting all the resources is just an
- 16:00Speaker 9: awesome opportunity.
- 16:01Speaker 8: Well, and I think that's why it's so important to
- 16:04Speaker 8: acknowledge the exhibitors that you are going to have at
- 16:07Speaker 8: the event, Nicolette, because they are truly that we can
- 16:12Speaker 8: lean in to their expertise as resources while while they're
- 16:17Speaker 8: and I think that's going to be a bonus part
- 16:19Speaker 8: of the event as well.
- 16:21Speaker 5: Absolutely, that's a great point.
- 16:23Speaker 10: And you know our history, we all came from PDS
- 16:27Speaker 10: from back in the day Pharmacy Development Services, and if
- 16:30Speaker 10: you know our r ogs might remember there was a
- 16:33Speaker 10: big PDS conference every February, and so that's the framework
- 16:37Speaker 10: that we're leaning into is it worked so well. It
- 16:40Speaker 10: was such a great conference, and so we're resurrecting that
- 16:43Speaker 10: and putting an entirely new spin on it.
- 16:46Speaker 5: And there were a few key folks.
- 16:49Speaker 10: Who who came to me because I've wanted to put
- 16:52Speaker 10: on a conference for years, but we had COVID, then
- 16:55Speaker 10: we had the whole dir apocalypse last year, and so
- 16:58Speaker 10: now it's finally time. You know, this is a good
- 17:00Speaker 10: time and pharmacies really need it, We need this collaboration.
- 17:04Speaker 10: So Bill Holmes actually came to me. We've been talking
- 17:07Speaker 10: actually since last April. I remember we were at aap
- 17:11Speaker 10: in San Diego, I believe when we were talking about it,
- 17:14Speaker 10: and Bill's like, we really need that conference back. We
- 17:16Speaker 10: really need that innovation, We really need that brain space.
- 17:19Speaker 10: You know, Bill's been in this industry a long time
- 17:22Speaker 10: and he's brilliant. Really, I've had the luxury of spending
- 17:25Speaker 10: some time with him and just listening to him and
- 17:27Speaker 10: listening to his history and listening to his vision for
- 17:31Speaker 10: the future of pharmacy.
- 17:32Speaker 5: Super smart guy.
- 17:34Speaker 10: And he was a Bill at RX safe and now
- 17:37Speaker 10: they're with icon under itw wonderful company, amazing technology. They
- 17:42Speaker 10: have some exciting new things that they're launching as well.
- 17:46Speaker 10: And Bill was the very first person who believed in
- 17:48Speaker 10: this conference and believed in Atrium X and did the
- 17:54Speaker 10: initial funding to say this conference has to happen. And
- 17:57Speaker 10: he's given me a lot of leeway to put, you know,
- 18:00Speaker 10: my flavor on it as to what I think should happen.
- 18:03Speaker 10: And we've you know, collaborated with all these folks brought
- 18:06Speaker 10: him in to bring all their flavor, so definitely.
- 18:09Speaker 5: Bill wouldn't have happened without him.
- 18:11Speaker 10: And then we also have Liberty and jerrymed and Jeremy
- 18:16Speaker 10: and Cole, and they came in very soon after Bill
- 18:21Speaker 10: because they were like, what's Bill doing, What's you know,
- 18:24Speaker 10: what's he working on?
- 18:25Speaker 5: So they were like, that sounds really good. We are in.
- 18:29Speaker 10: And so those three founding sponsors, if it wasn't for them,
- 18:32Speaker 10: we wouldn't we wouldn't be here today, and we wouldn't
- 18:34Speaker 10: be on the.
- 18:35Speaker 5: Precipice of an amazing event in two.
- 18:37Speaker 10: Weeks, So big shout out to them. And then we
- 18:39Speaker 10: have about a more than a dozen other exhibitors who
- 18:43Speaker 10: have shown huge support who have come on.
- 18:45Speaker 5: Board, and that's exactly right.
- 18:47Speaker 10: Each one of these companies has such amazing thought leaders
- 18:50Speaker 10: within it who are going to be at a TRIMX
- 18:53Speaker 10: and they're constantly innovating, They're constantly talking with pharmacies every
- 18:57Speaker 10: day solving challenges. So by us putting them all in
- 19:01Speaker 10: the soup together, I'm really excited.
- 19:04Speaker 7: Absolutely, absolutely. I know these organizations. Their minds are always
- 19:09Speaker 7: on fire. They always want to do something that's ahead
- 19:12Speaker 7: of the game in order to prepare us for what's
- 19:14Speaker 7: happening in the marketplace. And rather than reacting, this conference
- 19:19Speaker 7: is going to give us an opportunity to build a
- 19:21Speaker 7: new blueprint that we get to go to market with
- 19:24Speaker 7: and not have to react, not have to play catchup,
- 19:28Speaker 7: and we're going to rely on these vendors to be
- 19:30Speaker 7: part of that. I think of the expansion of compounding.
- 19:33Speaker 7: I think of the expansion of long term care at home,
- 19:37Speaker 7: and I have the expansion of remote patient monitoring and
- 19:40Speaker 7: how patients are going to be cared for and be
- 19:42Speaker 7: in touch with their community pharmacists so much more through technology.
- 19:47Speaker 7: When I think of those types of things, it does
- 19:50Speaker 7: bring me back to Donnie. Donnie kind of give us
- 19:54Speaker 7: an overview of some of the things that if you
- 19:58Speaker 7: were put in charge of this conference as a pharmacy owner,
- 20:01Speaker 7: what would you want to be talking about?
- 20:03Speaker 4: Wow, that's a really great question, you know, I led
- 20:06Speaker 4: with some of those. I'm really excited about the five
- 20:09Speaker 4: oh three b GLP ones we're seeing that be successful
- 20:13Speaker 4: in so many different areas and even states that you know,
- 20:17Speaker 4: we didn't think it was possible, like California and things.
- 20:20Speaker 2: We're seeing some new.
- 20:21Speaker 4: Markets emerge there to allow them to enter into that space.
- 20:25Speaker 4: I'm really excited to learn about that. I still believe
- 20:29Speaker 4: in long term care at home and what it can
- 20:31Speaker 4: do to transform a pharmacy's gross profit. I think that
- 20:35Speaker 4: is really important, and if people aren't maximizing that today,
- 20:39Speaker 4: they've got to always learning about new solutions. Right, So
- 20:43Speaker 4: the vendor list is always exciting for me in terms
- 20:46Speaker 4: of what's out there, what's new, what have I not
- 20:49Speaker 4: thought about in a while for my business that maybe
- 20:52Speaker 4: I need to lean into again, thinking about how we
- 20:56Speaker 4: can leverage all types of technology. Again, Nicolette alluded to
- 21:02Speaker 4: it in the very beginning, right, we're saying shrinking reimbursements.
- 21:05Speaker 4: It's a tough of a marketplace as it's ever been
- 21:07Speaker 4: to operate a pharmacy, and we need non human resource
- 21:13Speaker 4: support in ways that can really help us scale parts
- 21:16Speaker 4: of our business, and that's really what I'm looking forward
- 21:18Speaker 4: to learn.
- 21:19Speaker 10: Yeah, absolutely, I love the technology piece. I'm a huge
- 21:22Speaker 10: technology nerd, so I know we have our ex mile
- 21:27Speaker 10: who's going to be there. I actually need to look
- 21:28Speaker 10: into their solution because I just started a five o
- 21:31Speaker 10: three be fulfillment pharmacy here in Florida a few months
- 21:34Speaker 10: ago and we're struggling with some of the delivery logistics.
- 21:37Speaker 5: So I got to reach out to kunall over there.
- 21:39Speaker 5: And then of course we also have Sykes coming p.
- 21:43Speaker 10: Sykes is a huge proponent of independent pharmacy, always putting
- 21:47Speaker 10: out great free content for folks. IPC is an interesting
- 21:52Speaker 10: one too that I wanted to give a shout out
- 21:54Speaker 10: to the Independent Pharmacy Cooperative because God, you mentioned.
- 21:57Speaker 5: Remote patient monitoring.
- 21:58Speaker 10: IPC has a really cool new I Care plus digital
- 22:02Speaker 10: health platform and it ties in that it ties in
- 22:05Speaker 10: some telemedicine, weight loss clinics, really cool stuff I've been
- 22:09Speaker 10: watching with IPC that they're going to be talking about
- 22:12Speaker 10: at a TRIMX So that's amazing technology wise too. We
- 22:16Speaker 10: have heel now and so they have like a click
- 22:19Speaker 10: to pay solution where the patient can get a text
- 22:22Speaker 10: and then securely submit the payment online.
- 22:25Speaker 5: So I'm a tech nerd.
- 22:27Speaker 10: I love all the technology and gadgets and I'm super
- 22:31Speaker 10: excited to see what AI is going to do to
- 22:35Speaker 10: our industry. Pharmacy is so reactive. And our CTO at Atrium,
- 22:40Speaker 10: he has a long history in AI and he's done
- 22:43Speaker 10: projects in Dubai and everything, and projects in the construction
- 22:46Speaker 10: industry to kind of bring them up to speed. And
- 22:48Speaker 10: I told him, I'm like, yeah, I just can't believe
- 22:51Speaker 10: with AI. You know, my kids are going to be
- 22:53Speaker 10: able to say because, like we say, right, we used
- 22:56Speaker 10: to have to go to the encyclopedia. We didn't really
- 22:58Speaker 10: have the internet when we had to do a project.
- 23:00Speaker 10: We didn't have cell phones. We played Oregon Trail and
- 23:02Speaker 10: they're like what So when mys are adults, they're going
- 23:06Speaker 10: to tell their kids, well, we didn't have AI. That
- 23:09Speaker 10: was before we had AI, and their kids are.
- 23:11Speaker 5: Going to be like, I don't work sure, what do
- 23:14Speaker 5: you mean?
- 23:14Speaker 10: And I sold my CTO. I was like, yeah, so
- 23:16Speaker 10: in three to five years, I can't believe. He said,
- 23:19Speaker 10: three to five months, Wow, you won't believe the landscape
- 23:23Speaker 10: In three to five months, so what a time to
- 23:26Speaker 10: be alive.
- 23:27Speaker 8: Well, and kudos to Nicolette for recognizing the need to
- 23:31Speaker 8: bring that innovation into the pharmacy space, because I'm going
- 23:35Speaker 8: to guess that along with with technology and optimizing for
- 23:39Speaker 8: that in independent pharmacy, which other industries already do, right,
- 23:42Speaker 8: I mean, we know that we want to level up
- 23:45Speaker 8: our independent pharmacy owners so that they're thriving. And one
- 23:49Speaker 8: of the biggest pain points that I hear over and
- 23:52Speaker 8: over and over again is the people side of the business, right, the.
- 23:57Speaker 5: Team engagement.
- 23:58Speaker 8: How to manage Right now, independent pharmacy is one of
- 24:02Speaker 8: the few industries that I work with that is managing
- 24:06Speaker 8: across four generational cohorts all the way from gen zers
- 24:13Speaker 8: to baby boomers, And that's a tough nut to crack
- 24:17Speaker 8: in terms of team engagement, building a high performance team culture,
- 24:22Speaker 8: really performance management. How do you coach for that performance?
- 24:26Speaker 8: How do you make those boomers comfortable with the technology?
- 24:28Speaker 8: How do you get them to adopt and integrate and
- 24:32Speaker 8: utilize it? Conversely, how do you get the gen z
- 24:35Speaker 8: ers to really level up their interpersonal communication skills?
- 24:40Speaker 4: Right?
- 24:41Speaker 8: It is an interesting time to be a manager and
- 24:45Speaker 8: a leader, and so I have a sneaking, just a
- 24:48Speaker 8: small sneaking suspicion that that may be one of the
- 24:53Speaker 8: topics that comes up.
- 24:54Speaker 5: Yeah, I'm excited about.
- 24:55Speaker 7: Man, we can teach you to talk like these kids.
- 24:58Speaker 7: I love givty Alpha like I don't even know how
- 25:01Speaker 7: to like.
- 25:02Speaker 2: But I met.
- 25:04Speaker 7: My twelve year old daughter just to make her laugh.
- 25:07Speaker 7: She'll be like, please, don't say skivvy anymore.
- 25:09Speaker 10: Like to stop that, dad, that's way too Ohio, that
- 25:17Speaker 10: doesn't have enough riz.
- 25:18Speaker 5: I have a duel year as well at twelve or
- 25:19Speaker 5: thirteen and eleven. Oh my gosh. Yeah, I love it.
- 25:24Speaker 7: Well, I'm excited, Nicolette. I just want to thank you again,
- 25:28Speaker 7: like Kelly was saying, for putting it out there.
- 25:31Speaker 3: You know it. It's a little.
- 25:33Speaker 7: You know your your skin has been thick for years,
- 25:36Speaker 7: and I know that you weren't really worried about the pushback,
- 25:40Speaker 7: per se. But when you're doing something for the first time,
- 25:43Speaker 7: I've done two major things in the industry of pharmacy
- 25:47Speaker 7: for the very first time, the very first podcast put out,
- 25:50Speaker 7: and I remember calling people or texting people or talking
- 25:54Speaker 7: on the phone, Hey, would you listen to my podcast?
- 25:57Speaker 3: What's the podcast?
- 25:58Speaker 7: They didn't know in two thousand and nine what a
- 26:00Speaker 7: podcast was, and now today it's just like it's the
- 26:03Speaker 7: biggest way to consume information.
- 26:05Speaker 3: It's why that we've had the success that we've had.
- 26:07Speaker 7: Teaming up with people like you just get me excited
- 26:11Speaker 7: because I realize and I trust, I trust the people
- 26:14Speaker 7: that are coming to this that the interest of their
- 26:18Speaker 7: futures to empower pharmacy for our futures. And I think
- 26:23Speaker 7: that that's whole cultivating of ideas. It's just going to
- 26:29Speaker 7: become I think one of the biggest conferences in pharmacy
- 26:32Speaker 7: because when people realize, oh my goodness, I can be
- 26:36Speaker 7: part of shaping something that will impact not only my
- 26:40Speaker 7: community pharmacy, but thousands of pharmacies across the nation.
- 26:44Speaker 3: I think that's really super special.
- 26:46Speaker 10: Yeah, I'm just super excited about it and so thankful
- 26:49Speaker 10: for the trust that everyone's placed in me and in
- 26:53Speaker 10: the team we were able to pull together the band
- 26:56Speaker 10: that's like the back of house band that made the
- 26:58Speaker 10: PDS conference that it was, and so they're working behind
- 27:02Speaker 10: the scenes on all the things that are way too
- 27:04Speaker 10: overwhelming for me. And then if you're in my cell phone, sorry,
- 27:08Speaker 10: but I've been blowing you up, begging you to come
- 27:11Speaker 10: to this conference, and almost everybody's like, yes, we'll be there,
- 27:16Speaker 10: we'll support you, and I just I can't appreciate that
- 27:18Speaker 10: enough because I'm definitely not the smartest person in the room.
- 27:22Speaker 5: I'm just persistent.
- 27:23Speaker 4: So I think our kids would say that adriam X
- 27:28Speaker 4: is going to be fire.
- 27:30Speaker 2: No cap.
- 27:34Speaker 3: Arimax twenty twenty five.
- 27:36Speaker 7: It's on February twenty seventh through March first. It's going
- 27:40Speaker 7: to be in the beautiful Margaritaville Resort in Orlando, Florida.
- 27:47Speaker 7: I cannot wait to get out of the Pittsburgh weather
- 27:50Speaker 7: and actually get some sunshine. So it better be a
- 27:52Speaker 7: nice week that week.
- 27:54Speaker 10: Nicolabs it's beautiful weather here in Tampa right now. It's
- 27:57Speaker 10: eighty three degrees. I don't say I know it. Valentine's weekend.
- 28:01Speaker 10: So Valentine's what I'm doing for my Valentines is I'm
- 28:06Speaker 10: actually scoping out locations for twenty twenty six.
- 28:12Speaker 5: Of course, I mean the first event.
- 28:14Speaker 10: Thanks to all of you and everyone who's committed, it's
- 28:18Speaker 10: a huge success already and.
- 28:20Speaker 5: I know it's going to be magical and we're going to.
- 28:23Speaker 10: Do it even bigger in twenty twenty six, and so
- 28:26Speaker 10: we're going to lock in that venue as soon as
- 28:28Speaker 10: we can. And I'm taking my kids with me too,
- 28:30Speaker 10: so that they can start to learn how to scout
- 28:32Speaker 10: out hotel locations for events.
- 28:34Speaker 11: So we sign one oh one.
- 28:37Speaker 3: That's right, awesome, Well, thank you so much.
- 28:40Speaker 7: Pharmacy Podcast Network is the official media partner of Atrium
- 28:44Speaker 7: x happening at the end of this month.
- 28:47Speaker 3: Do not miss it.
- 28:48Speaker 7: Make sure that you go to Atrium twenty four dot
- 28:51Speaker 7: io once again, that's a Trium twenty four dot io
- 28:55Speaker 7: to sign up. You'll find it under the conference section.
- 28:59Speaker 7: If you have any questions, reach out to the Pharmacy
- 29:01Speaker 7: Podcast Network will get to the registration directly. But once
- 29:05Speaker 7: again Atrium twenty four dot h. And with that, Twerus
- 29:09Speaker 7: is out till next week. Thanks for listening. Subscribe on
- 29:13Speaker 7: all of your podcast platforms.
- 29:15Speaker 3: We will see you in Orlando.
- 29:20Speaker 12: Next. On the second half of Twerks, we talk with
- 29:23Speaker 12: doctor Julie Schultz, md MPH and doctor Michael Dividio farm
- 29:28Speaker 12: D from Avalon Health talk about the challenges of quick
- 29:32Speaker 12: fixed treatments and weight management plans with the inclusion of
- 29:35Speaker 12: GLP ones from the article titled how to maximize the
- 29:39Speaker 12: value of GLP one drugs while improving health equity, Julie
- 29:44Speaker 12: and Mike talk about the real world needs of people
- 29:47Speaker 12: who want to lose weight doing it the right way for.
- 29:50Speaker 2: Long term benefit.
- 29:51Speaker 12: Due to the continued high cost, only patients with greater
- 29:55Speaker 12: financial resources or those with generous employer sponsored drug benefits
- 29:59Speaker 12: will be able to afford the medications for obesity. This
- 30:03Speaker 12: can exacerbate health inequities, likely driving significantly higher costs for
- 30:08Speaker 12: public and commercial health plans intensified by the new financial
- 30:12Speaker 12: strain from weight loss medications. Rather than denying coverage for
- 30:16Speaker 12: GLP ones for obesity, health plans could modify eligibility policies
- 30:22Speaker 12: to require data from a standardized set of laboratory tests
- 30:26Speaker 12: and other biometrics to identify patients in most need of
- 30:30Speaker 12: GLP ones and verify medical necessity. This approach would reduce
- 30:34Speaker 12: inappropriate prescribing while ensuring that patients who are most likely
- 30:38Speaker 12: to benefit from the drugs have access to them.
- 30:43Speaker 7: Hey, welcome back to this Week in Pharmacy. This is
- 30:46Speaker 7: a special interview segment. It's exciting to attract multiple different
- 30:50Speaker 7: perspectives when we're talking about different things in pharmacy trickling
- 30:55Speaker 7: over from community to specialty to geriatrics. Our focus in
- 30:59Speaker 7: pediatrics something that's come up in the market. I certainly
- 31:02Speaker 7: don't have to tell you. The Pharmacy Podcast Network listeners,
- 31:05Speaker 7: you've heard many of our podcast touch on getting access
- 31:09Speaker 7: to medications that are on the short list and that
- 31:14Speaker 7: you don't have access to what your patient needs, and
- 31:17Speaker 7: it's frustrating everybody. It's frustrating your physician's team, and the
- 31:21Speaker 7: follow up in the pharmacy obviously, so access to g
- 31:25Speaker 7: LP one drugs. With the popularity of the explosion with
- 31:30Speaker 7: weight loss and people trying to change their lives for
- 31:34Speaker 7: the better, obesities run a muck in our nation. So
- 31:38Speaker 7: this is a really important topic today. I want to
- 31:41Speaker 7: say welcome to doctor Mike de Veto. He's a farm
- 31:45Speaker 7: d a pharmacist with eight years of clinical expertise, and
- 31:49Speaker 7: he's from Pittsburgh, Pennsylvania, went to Pittsburgh, Pennsylvania du Cane University.
- 31:53Speaker 3: Mike, it's great to have you.
- 31:56Speaker 2: Yeah, thank you, Todd, great to be here.
- 31:58Speaker 7: We also have JULIEZ. Doctor Julie Schultz is VP of
- 32:02Speaker 7: Product at Avalon Health Solutions and is a physician, executive
- 32:06Speaker 7: and product leader and really understands the full three hundred
- 32:11Speaker 7: and sixty. I always say, Julie, the quarterback of the
- 32:14Speaker 7: pharmacy or the clinical teams out there, the patient management
- 32:18Speaker 7: teams out there are quarterback pitching the ball to people
- 32:22Speaker 7: like people like Mike.
- 32:23Speaker 3: Welcome to the show, Happy to be here.
- 32:26Speaker 7: I hope you like football because it's football season right now,
- 32:29Speaker 7: so I'll I'm all hypered up. My Steelers aren't in
- 32:33Speaker 7: and I've transferred my allegiance to the Bills, so that'll
- 32:37Speaker 7: publicly put it out there.
- 32:39Speaker 2: That's my yeah about college. Are you an Ohio State fan?
- 32:43Speaker 2: Because they had a big win.
- 32:44Speaker 7: Yukon Baby Yukon Husky. My god son, Jilani Stafford, defensive
- 32:50Speaker 7: tackle was just in the Wasabi Bowl and he was
- 32:54Speaker 7: featured on ESPN and then he was in the Dream Bowl,
- 32:58Speaker 7: which was his second follow up, and he will be
- 33:00Speaker 7: looked at by the NFL in between now and March.
- 33:05Speaker 7: So we're keeping lookout for Johnny Stafford from you.
- 33:08Speaker 2: KURR.
- 33:09Speaker 3: Yeah, very cool.
- 33:11Speaker 7: Well, I'm excited about today's discussion Julie and Mike. We
- 33:15Speaker 7: want to have a podcast episode for these listeners, These
- 33:19Speaker 7: pharmacy physician teams that are out that are they're dealing
- 33:23Speaker 7: with this explosion of interest and the patient wants it quick.
- 33:27Speaker 7: And we are in a nation where we think of
- 33:31Speaker 7: this quick fix. Hey, give me my shot every thirty
- 33:33Speaker 7: days or every day or however often.
- 33:35Speaker 3: You guys have to go.
- 33:36Speaker 7: Through it and my life's just going to magically change.
- 33:39Speaker 7: And as clinicians and as pharmacists of what they see
- 33:42Speaker 7: throughout the community, that's just not the case. And it's like, okay,
- 33:46Speaker 7: let's talk about what's really happening behind the scenes. Let's
- 33:49Speaker 7: give our listeners today to really unpack this. And I'm
- 33:52Speaker 7: going to kick this off to Julie first just to
- 33:57Speaker 7: kind of set the stage. How can I health plan
- 34:01Speaker 7: or employers, how can they kind of dial in and
- 34:04Speaker 7: improve access to our GLP one drugs for the underserved
- 34:08Speaker 7: and the vulnerable patient populations out there who are also
- 34:12Speaker 7: going through obesity, they're suffering with something they just can't
- 34:15Speaker 7: get over, the hamp no matter what they try, and
- 34:18Speaker 7: the GLP one it just gives you like this bump
- 34:21Speaker 7: and advantage to take that first big step to kind
- 34:24Speaker 7: of unpack that for our listeners.
- 34:27Speaker 13: Yeah, well, and I think first, let's take a step
- 34:28Speaker 13: back and understand the state of coverage for these drugs today.
- 34:32Speaker 13: I mean, historically they most plans are covering them for diabetes,
- 34:37Speaker 13: but more recently we have expanded indications into prevention car
- 34:42Speaker 13: of cardiovass major advers cardiovascular events for obesity, as you
- 34:46Speaker 13: mentioned now obstructive sleep apnea, with potential expanding indications into
- 34:52Speaker 13: heart failure, chronic kidney disease, and so we're at a
- 34:55Speaker 13: point where feasibly more than half of the US popular
- 35:00Speaker 13: could potentially qualify for these drugs. However, as you've mentioned, Todd,
- 35:04Speaker 13: we've got extreme shortages and frankly, the bigger problem is
- 35:08Speaker 13: that we simply can't afford these drugs at the price
- 35:11Speaker 13: tag that they're at today. And what's happened is that
- 35:15Speaker 13: we've really they're very unequal coverage of these drugs. For
- 35:19Speaker 13: obesity in particular, a lot of plans have initially provided coverage,
- 35:23Speaker 13: such as North Carolina Blue Cross of Michigan, but really
- 35:28Speaker 13: realized that that was bankrupting their programs and had to
- 35:31Speaker 13: actually pull back coverage. And when we talk about especially
- 35:34Speaker 13: health equity and the clinical need here, I think.
- 35:37Speaker 3: We would all agree that a black or.
- 35:40Speaker 13: White approach and all or nothing approach covering everyone for
- 35:42Speaker 13: obesity or not is probably not what's best for patients.
- 35:46Speaker 13: And so that's really I think the problem that we
- 35:49Speaker 13: need to solve most immediately is trying to understand beyond diabetes,
- 35:53Speaker 13: who are the patients that we're going to cover, who
- 35:56Speaker 13: are the patients that are going to need these drugs most,
- 35:59Speaker 13: and who's going to benefit. And that's I think where
- 36:02Speaker 13: employers and health plans are really starting to uh to
- 36:06Speaker 13: work together today. Mike.
- 36:08Speaker 7: I'm thinking of this from your perspective and what you
- 36:11Speaker 7: guys go through. You get that, you get your order
- 36:13Speaker 7: in any any setting community long term care, and now
- 36:18Speaker 7: you go to fill it's not available. You have challenges
- 36:24Speaker 7: maybe with getting it covered under insurance and some normal
- 36:28Speaker 7: land I mean, our our ecosystem of patient care. But
- 36:32Speaker 7: what are patient's most significant barriers to the access of
- 36:35Speaker 7: GLP one drugs and and how can that be addressed?
- 36:39Speaker 2: I mean, in my mind, the two biggest components of barriers.
- 36:42Speaker 2: Number one is cost. Right, if the drugs too expensive,
- 36:45Speaker 2: the patient's not going to get in. And some of
- 36:49Speaker 2: this comes down to, as Julie was saying, what is
- 36:52Speaker 2: the coverage criteria from the health plan perspective, because ultimately
- 36:57Speaker 2: the coverage criteria that's sort of posted in the PO
- 37:00Speaker 2: is what the plan is going to cover the drug
- 37:02Speaker 2: for at the cheaper copay or what the patient's going
- 37:06Speaker 2: or conversely, what the patient's going to pay cash or
- 37:08Speaker 2: the higher price out of pocket for. So cost is
- 37:11Speaker 2: the first thing, and I'll give you perspective here in
- 37:13Speaker 2: real dollars, I mean, the cash price of a GOLP
- 37:16Speaker 2: one from a pharmacy is around twelve hundred bucks a month.
- 37:20Speaker 2: That's pretty expensive. And if you're you know, low income
- 37:22Speaker 2: or vulnerable patient, chances are you don't have twelve hundred
- 37:25Speaker 2: dollars a month to pay for this, even if it
- 37:27Speaker 2: is to Julie's point, you know, going to treat something
- 37:31Speaker 2: beyond just obesity or diabetes, like cardio metabolic health, cardiovascular
- 37:36Speaker 2: decrease in cardiovascular risk. So anyway, so you know, cost
- 37:43Speaker 2: is a big portion. And as Julie said, when plans
- 37:46Speaker 2: make these sort of black and white decisions of we're
- 37:49Speaker 2: going to cover all patients who are diabetics or all
- 37:51Speaker 2: patients who are weight loss for these drugs, a lot
- 37:55Speaker 2: of times you know quite Frankly, there's not enough money
- 37:58Speaker 2: to go around around. And so unless there's a more
- 38:03Speaker 2: sort of prescribed, no pun intended approach to how the
- 38:08Speaker 2: dollars are spent for these types of drugs, chances are,
- 38:12Speaker 2: as a plan, you end up in a position where
- 38:13Speaker 2: you just don't have enough money to go around for everybody.
- 38:15Speaker 2: So cost is really the big thing. The number two
- 38:19Speaker 2: problem in my mind, as you kind of alluded to earlier,
- 38:21Speaker 2: is access right, And when I think about it from
- 38:25Speaker 2: a pharmacist perspective, from a dispensing role perspective, First of all,
- 38:30Speaker 2: these drugs require prior off right, which means that the
- 38:34Speaker 2: particular patient is getting approved for a particular drug. And
- 38:38Speaker 2: when I mean particular drug, like there's four or five
- 38:42Speaker 2: glp ones, Mount Jarro has gip in it two. But
- 38:45Speaker 2: you know kind of factor that into the class of medicine. Well,
- 38:48Speaker 2: that PA approval may only be for one specific you know,
- 38:52Speaker 2: formulation or product within that class. And if your pharmacy
- 38:56Speaker 2: either can't get access to that drug or or that
- 39:00Speaker 2: drug is on national back order. Think ozembic for a while,
- 39:04Speaker 2: and what are you supposed to do From a pharmacist perspective,
- 39:06Speaker 2: I mean it ends up in this like run around
- 39:08Speaker 2: from a patient of you know, I need to go
- 39:12Speaker 2: to my pharmacists to get this drug, but they don't
- 39:14Speaker 2: have it, so then I have to go back to
- 39:15Speaker 2: my doctor to get them to change the order, which
- 39:18Speaker 2: then requires a new prior off from the insurance to
- 39:20Speaker 2: then go back to the pharmacy and hopefully have the
- 39:23Speaker 2: drug and stock at that point. And it becomes even
- 39:26Speaker 2: more of a problem when you're talking about a population,
- 39:29Speaker 2: a vulnerable population who maybe doesn't have the means to
- 39:34Speaker 2: travel back and forth to the provider's office or to
- 39:37Speaker 2: the pharmacy. You know, in rural areas. I'm sure everybody's
- 39:41Speaker 2: aware of the term pharmacy desert, but in some of
- 39:43Speaker 2: the more rural areas where it's really difficult to get
- 39:47Speaker 2: to a pharmacy it maybe, you know, fifteen plus miles
- 39:50Speaker 2: away and transportation is an issue. Going back to the
- 39:54Speaker 2: pharmacy over and over again. From a patient perspective is
- 39:57Speaker 2: just it's nearly impossible. So it's you know, it kind
- 40:03Speaker 2: of stinks from a from a patient's perspective, because you
- 40:05Speaker 2: want this drug, you want you want that first step
- 40:10Speaker 2: in kind of leading you to the path of lifestyle
- 40:13Speaker 2: changes to getting you to a healthier state. But when
- 40:15Speaker 2: it's just so incredibly difficult to get to that point,
- 40:19Speaker 2: it just makes it possible from the patient's perspective to
- 40:21Speaker 2: uh to even start these mets.
- 40:24Speaker 7: So I think of the rings to get us the access. Julian,
- 40:29Speaker 7: as you were talking and now Mike did an amazing
- 40:32Speaker 7: follow up from a pharmacist perspective, I'm saying rings just
- 40:36Speaker 7: from a visual but I think of where do we
- 40:39Speaker 7: start to start giving the medications without it being bias
- 40:48Speaker 7: UH and starting with something that maybe FDA approval for
- 40:51Speaker 7: the indication and for the usage of it. How how
- 40:55Speaker 7: do we make decisions how do health systems ensure equitable
- 40:59Speaker 7: distribution of a g l P one, especially for patients
- 41:02Speaker 7: with diabetes, Like how do you how do you work
- 41:06Speaker 7: that rebis cube out?
- 41:08Speaker 13: Yeah, great question. So I think it I think it
- 41:11Speaker 13: starts with and might kind of started to paint the
- 41:13Speaker 13: picture of this patient journey but also the journey of
- 41:17Speaker 13: all the physicians and providers involved in the complexity of
- 41:20Speaker 13: all of that. And so I think we need to
- 41:22Speaker 13: think about, you know, programs or technology enabled solutions that
- 41:26Speaker 13: that really streamline that process all the way starting from
- 41:29Speaker 13: the beginning, So looking riskstratifying your population, identifying patients who
- 41:34Speaker 13: are going to be who are most going to most
- 41:36Speaker 13: benefit from the drugs. The way that we've that things
- 41:40Speaker 13: are panning out today where we have kind of these
- 41:43Speaker 13: black or white coverage criteria, is that a lot of
- 41:47Speaker 13: times the physicians who have more time, the physicians who
- 41:51Speaker 13: have more resources are going to be able to get
- 41:53Speaker 13: those prior authorizations that we're going to be able to
- 41:56Speaker 13: potentially get, you know, drugs for patients who may not
- 41:59Speaker 13: full meet the criteria. For example, we see in our
- 42:02Speaker 13: data that twenty to thirty percent of the prescriptions for diabetics,
- 42:06Speaker 13: those patients don't actually have supporting lab values supporting hemoglobin
- 42:11Speaker 13: a one C lab value suggestive of diabetes that is
- 42:16Speaker 13: out of control. And so there's a lot we can
- 42:18Speaker 13: be doing on the front end to look at these
- 42:21Speaker 13: lab values, identify markers of broader cardio metabolic health, some
- 42:25Speaker 13: of the other comorbidities that I've mentioned, such as cardiovascular disease,
- 42:29Speaker 13: sleep apnea, chronic kidney disease. We can take those lab
- 42:32Speaker 13: values and proactively start to identify patients who are going
- 42:36Speaker 13: to benefit the most and start working through some of
- 42:40Speaker 13: the care team, whether that's the pharmacists, whether that is
- 42:43Speaker 13: care managers, whether that is other folks you know that
- 42:48Speaker 13: are part of the physician care team, to work with
- 42:51Speaker 13: those patients first and really kind of pull them through
- 42:55Speaker 13: the process in a way that supports them and make
- 42:57Speaker 13: sure that this is, you know, there's some shared patient
- 43:00Speaker 13: decision making. And our hope is that by being proactive
- 43:05Speaker 13: in a very similar way to a lot of the
- 43:07Speaker 13: diabetes or kind of kidney disease programs are today and
- 43:10Speaker 13: helping to manage these very cardio metabolically as sick patients,
- 43:15Speaker 13: we can not only make sure that they're you know,
- 43:17Speaker 13: we're getting the drugs to the sickest patients, but then
- 43:19Speaker 13: also that we're supporting them in their journey and making
- 43:23Speaker 13: sure that they have all the ancillary services including diet, exercise,
- 43:27Speaker 13: et cetera to help them along the way.
- 43:30Speaker 7: So I'm fascinated by pharmacogenomics. I first learned to even
- 43:35Speaker 7: say that word in twenty sixteen, where I was able
- 43:39Speaker 7: to help build a mobile application that allowed a physician
- 43:43Speaker 7: to put in some criteria and then hit the nenter
- 43:46Speaker 7: button and come up with tying it back to ICED nine,
- 43:51Speaker 7: which is now ICD ten and CPT codes if the
- 43:54Speaker 7: patient was eligible for reimbursement of that test based on
- 43:58Speaker 7: the parameters that were available. And we pulled a bunch
- 44:01Speaker 7: of data from the FDA's websites as to which of
- 44:04Speaker 7: the medications were more likely to need the test for metabolism,
- 44:07Speaker 7: and blah blah blah.
- 44:08Speaker 3: It was so interesting. Fascinates me.
- 44:10Speaker 7: Now fast forward, we have a show on the PPN
- 44:13Speaker 7: network that does nothing but dissects the world of condition
- 44:17Speaker 7: medication and pharmacogenomics tests. So this starts pinging my my
- 44:23Speaker 7: non clinical ears to to be able to think, Hey,
- 44:26Speaker 7: how does how does that play into the lab testing?
- 44:30Speaker 7: What lab are we testing? What is it? Is it
- 44:33Speaker 7: a gene or is it a way that there there
- 44:37Speaker 7: was you know, responding to the medication initially in order
- 44:41Speaker 7: for us to dial in so that like you're saying,
- 44:43Speaker 7: the highest candidate in whatever you know, level that you're building,
- 44:49Speaker 7: whatever kind of chart that you're building, that this this,
- 44:53Speaker 7: this candidate rises to the top, so that we make
- 44:56Speaker 7: sure that they're getting the you know, preferent I don't
- 44:59Speaker 7: want to say press diferential treatment based on condition versus
- 45:02Speaker 7: preferential treatment on income level or where they live or.
- 45:07Speaker 3: You know what culture they're in. Like it. That's fascinating.
- 45:10Speaker 7: So before we get into kind of like our next subject,
- 45:14Speaker 7: I'd like to get around in the health equity. I
- 45:16Speaker 7: wanted you to chime into some of the lab the
- 45:19Speaker 7: labs that you're able to dial in on.
- 45:22Speaker 13: Yeah. Absolutely, So today what we're looking at is I
- 45:25Speaker 13: mentioned hemogob and a n C, but there's also other
- 45:27Speaker 13: markers that we can use across the cardiometabolic spectrum, including
- 45:33Speaker 13: your your lipid panels, your kidney markers, liver function. I
- 45:39Speaker 13: think what you're starting to speak about is some of
- 45:40Speaker 13: the genetic causes. LP LITTLA or libolprotein little as is
- 45:45Speaker 13: a marker that we can see that it has a
- 45:47Speaker 13: primarily genetic cause of cardiovascular disease. That can help patients
- 45:52Speaker 13: who you know, who might need a specific treatment more
- 45:56Speaker 13: tailored toward that background. But I think the horizon is
- 46:00Speaker 13: really exciting. We don't know of any a lot of
- 46:03Speaker 13: single genes that contribute to cardivasrom disease. It's most likely
- 46:07Speaker 13: a polygenics and many genes contributing to the disease. But
- 46:11Speaker 13: I think that's absolutely the direction we're headed is uncovering
- 46:14Speaker 13: polygenic patterns of different phenotypes of the disease. Patients who
- 46:18Speaker 13: are more gut driven or brain driven that might be
- 46:21Speaker 13: more likely to respond to certain types of medications, and
- 46:24Speaker 13: so that'll really help not just withheld equity, but he's
- 46:27Speaker 13: also the person of the combined personalization of the right
- 46:29Speaker 13: treatment for the right patient.
- 46:32Speaker 2: But even as it stands sort of today, Todd, it's
- 46:35Speaker 2: you know, the markers that Julie's talking about, they're pretty routine.
- 46:39Speaker 2: I mean we're not talking complex genetic tests here. We're talking,
- 46:42Speaker 2: you know, just just your sort of normal blood. I mean,
- 46:45Speaker 2: anyone see is like a fingerstick. It's a pretty standard
- 46:48Speaker 2: lab test when it's done. The sort of I guess
- 46:52Speaker 2: groundbreaking innovation here is it's it's taking those values, those
- 46:57Speaker 2: objective numbers, and it's starting to use use them to
- 47:01Speaker 2: paint the picture of coverage criteria, which is not typically
- 47:04Speaker 2: something that's that's normally done today, you know, in our
- 47:08Speaker 2: sort of future state possibilities. It's taking those values and
- 47:12Speaker 2: it's you know auto approving prior off for the patients
- 47:16Speaker 2: that meet certain types of uh, you know, qualifying criteria
- 47:19Speaker 2: where where you can literally say objectively by their lab values,
- 47:23Speaker 2: this is a very sick patient who should not have
- 47:25Speaker 2: a prior off for this. And then when you add
- 47:28Speaker 2: on the sort of procurement complexity, right, is the pharmacy
- 47:32Speaker 2: had a stock on it? Is there an opportunity there
- 47:34Speaker 2: to say, well, we're not just going to approve the
- 47:36Speaker 2: PA for aunt Jarrow, but we're going to approve the
- 47:39Speaker 2: PA for the class of GLP once. That way, you know,
- 47:43Speaker 2: the pharmacists, it's almost kind of like a collaborative practice
- 47:46Speaker 2: agreement in a way, right, where the pharmacists can kind
- 47:48Speaker 2: of make the decision on which sort of level of
- 47:51Speaker 2: gnlple and the patient's going to get. But in the
- 47:54Speaker 2: case of say ozebic being on national back order or
- 47:58Speaker 2: Trulicity being out of stock or whatever, that the pharmacy
- 48:01Speaker 2: can just reach for the next best GLP one and
- 48:03Speaker 2: have it covered. So you're not in that sort of
- 48:05Speaker 2: run around cycle.
- 48:06Speaker 4: Right.
- 48:07Speaker 2: You already kind of verify objectively through the values that
- 48:09Speaker 2: that patient is sick and needs this, So let's remove
- 48:13Speaker 2: all the barriers if we possibly can. Let's do it
- 48:15Speaker 2: in an automated fashion to help support better support the
- 48:19Speaker 2: staff at the doctor's office who are sitting there reviewing
- 48:23Speaker 2: prior offs or submitting the prior off paperwork, and the
- 48:26Speaker 2: administrative staff of the health plan. Right, there's pharmacists that
- 48:29Speaker 2: work and manage care who day in and day out
- 48:31Speaker 2: just sit and review patient charts and give it a
- 48:33Speaker 2: stamp of approval or denial. Well, our future vision is like,
- 48:36Speaker 2: let's automate that with lab values.
- 48:40Speaker 7: Yeah, you make me want to don my boxing gloves
- 48:45Speaker 7: so we can start punching the PBM out of the
- 48:48Speaker 7: out of the mix and let our physician environmisists do
- 48:52Speaker 7: their let them let them cook, as they say on TikTok,
- 48:55Speaker 7: let them cook.
- 48:58Speaker 3: But yeah, that's a whole another podcast.
- 49:00Speaker 7: While bringing back for a discussion on PBMs and health equity,
- 49:07Speaker 7: So I really want to understand kind of like the
- 49:10Speaker 7: cost affordability, our next steps high cost medications, the GLP drug,
- 49:17Speaker 7: the effect on the patient, the ability to maintain consistent
- 49:21Speaker 7: treatment plans. What are some of your ideas, Julie, to
- 49:24Speaker 7: to kind of get to the next step.
- 49:28Speaker 13: Yeah, I think that's that's a huge piece of it
- 49:31Speaker 13: is that we've seen so many patients who go on
- 49:33Speaker 13: the drugs and then either because of affordability issues, drug
- 49:37Speaker 13: tolerance issues, discontinue them. And so I think that's another
- 49:41Speaker 13: element of I think, you know, this program is how
- 49:43Speaker 13: can we support those patients and how can we, you know,
- 49:48Speaker 13: make sure that they understand what they're getting themselves into, right,
- 49:52Speaker 13: I think patient choice and being able to determine not
- 49:55Speaker 13: just looking at GLP one drugs, but also potentially bariatric
- 49:58Speaker 13: surgery is an option, or their weight loss drugs. There
- 50:01Speaker 13: is definitely not a you know, one size fits all,
- 50:05Speaker 13: and I think what we're seeing the successful model that
- 50:07Speaker 13: that that approaches this is really a more of a collaborative,
- 50:12Speaker 13: multidisciplinary approach where we're seeing cardio metabolic centers of excellence
- 50:16Speaker 13: popping up where you can really bring all of those
- 50:19Speaker 13: specialties and expertise together to develop that tailored and personalized
- 50:24Speaker 13: approach for patients. Mike, anything to add from the pharmacistive perspective,
- 50:29Speaker 13: I think this is an area where a lot of
- 50:31Speaker 13: times the physicians write the prescription and never look back.
- 50:36Speaker 9: Uh.
- 50:37Speaker 13: But but I know that tolerability and adherence is a
- 50:41Speaker 13: challenge for these drugs.
- 50:43Speaker 2: Yeah, No, I mean, and I would I would go
- 50:44Speaker 2: back to the earlier comment that I made about, you know,
- 50:47Speaker 2: in this sort of future state vision here if the
- 50:51Speaker 2: PA approval on file is not just for the specific drug,
- 50:55Speaker 2: but for the class of drugs. Right, Because to your point, Julie,
- 50:59Speaker 2: you know, a paid should may be prescribed Mount Jaro,
- 51:02Speaker 2: there's a time period at which the patient needs to
- 51:05Speaker 2: become adjusted to the drug. Right. A lot of patients
- 51:08Speaker 2: have side effects in the first few weeks of trying
- 51:10Speaker 2: to do medication. So if there is an opportunity again
- 51:15Speaker 2: I'm talking future sort of vision state here, but if
- 51:17Speaker 2: there was an opportunity where the pharmacist, who by the way,
- 51:21Speaker 2: is seeing the patient way more often no offense than
- 51:24Speaker 2: that the provider is right. I mean, if this is
- 51:26Speaker 2: a monthly refill, the pharmacist to see in that patient
- 51:29Speaker 2: on a monthly basis, right, there's more constant communication there,
- 51:33Speaker 2: And I think that's important to bring in here because
- 51:35Speaker 2: we're talking about lifestyle changes and that requires constant re
- 51:40Speaker 2: upping and constant communication. And it's a long process to
- 51:43Speaker 2: get to a lifestyle change. But you know, on that
- 51:46Speaker 2: care journey, if the patient kind of voices to the pharmacists, hey,
- 51:50Speaker 2: this dose or this drug is causing me side effects
- 51:55Speaker 2: that I don't think I can keep taking this that
- 51:57Speaker 2: there needs to be an easier way for that pharmacist
- 51:59Speaker 2: to like adjust the drug to something different, whether it's
- 52:03Speaker 2: by way of collaborative practice agreement, and that kind of
- 52:07Speaker 2: boils down to, you know, like the doctor gives authority
- 52:10Speaker 2: to the pharmacist to make those decisions. But also, you know,
- 52:15Speaker 2: the coverage aspect of it, because again we're talking price
- 52:18Speaker 2: and we can't shift from one drug to the next
- 52:21Speaker 2: and go from a five dollars copay to a twelve
- 52:24Speaker 2: hundred dollars copay because no patient's gonna want to buy
- 52:27Speaker 2: that twel hundred dollar drug. They're going to put up
- 52:28Speaker 2: with the side effects and the five dollars drug. So really,
- 52:31Speaker 2: it really, you know, it comes down to, like the
- 52:33Speaker 2: health plan needs to square to PBM whoever's paying you
- 52:37Speaker 2: know for that that patient's insurance profile or whatever where
- 52:40Speaker 2: it's paying for that drug. It needs to be aligned
- 52:43Speaker 2: with the provider and the pharmacy.
- 52:47Speaker 7: So there's a big surge in our network. There's a
- 52:49Speaker 7: big surge in preventative pharmacy care versus you know, trying
- 52:55Speaker 7: to catch up when somebody is really hypertension got out
- 52:58Speaker 7: of control, and I think of I think of drugs
- 53:04Speaker 7: that have long, long term impact long like what is
- 53:10Speaker 7: the long term impact for diabetes, obesity, in cardio metabolic disorders.
- 53:18Speaker 7: And I just said in opening the show, we are
- 53:22Speaker 7: the American you know, attitude is, let me get a
- 53:26Speaker 7: pill for that, and it's just going to magically change
- 53:29Speaker 7: my life. And it's like, no, that's one part of
- 53:33Speaker 7: your total environment and health. Maybe maybe you know, you
- 53:37Speaker 7: tie trade off of something or maybe you stay on
- 53:40Speaker 7: it for a long time, but you adjust your exercise
- 53:43Speaker 7: in how you're eating and water intake.
- 53:46Speaker 3: And there's a hole. I mean, each one of us
- 53:48Speaker 3: is a.
- 53:49Speaker 7: Petri dish slash science project about how we can dial
- 53:53Speaker 7: in I think of compounding. I think of the pharmacies
- 53:56Speaker 7: out there who dial into compounding for the shortage side
- 54:00Speaker 7: of things, but then also customizing medication regimens and and
- 54:05Speaker 7: so this is fascinating. This fascinating to me to think
- 54:09Speaker 7: of this next level of patient care that I think
- 54:13Speaker 7: is going to be a lot more dialed in, a
- 54:14Speaker 7: lot more customized into the future. But how did gl
- 54:18Speaker 7: P one drugs impact the long term you know, patient
- 54:22Speaker 7: in this in this hotbed of topic of you know,
- 54:26Speaker 7: it's like jump on the GLP one bandwagon. Julie, what
- 54:30Speaker 7: do you think, Oh.
- 54:31Speaker 13: Gosh, I don't think we know entirely, but I think,
- 54:35Speaker 13: you know, a couple of things.
- 54:36Speaker 3: First, we this drug class has been around for a while.
- 54:39Speaker 13: I think we feel pretty confident in the safety profile
- 54:42Speaker 13: of the drugs. Uh, some of the newer GLP one
- 54:47Speaker 13: certainly would want to follow the you know, the safety profile.
- 54:50Speaker 13: But it does seem like, you know, for the population study,
- 54:53Speaker 13: that the benefits far outweigh the risks. I think the
- 54:58Speaker 13: expanding indications is really fascinating to me, especially some of
- 55:02Speaker 13: the sort of neuropsychological impacts. If you think about some
- 55:05Speaker 13: of the research being done on behavior modification and addiction,
- 55:11Speaker 13: or even you know, starting to think about Alzheimer's and
- 55:13Speaker 13: dementia as a component of cardio metabolic disease, and is
- 55:17Speaker 13: there a role for GLP ones in Alzheimer's prevention. I
- 55:22Speaker 13: think that very very early, you know research. But when
- 55:24Speaker 13: I was at the American Heart Association, a lot of
- 55:26Speaker 13: posters starting to kind of think about those those links.
- 55:30Speaker 13: I think, you know, two things that are going to
- 55:32Speaker 13: be tangible. One is I do think this is creating
- 55:36Speaker 13: somewhat of a reorientation of the way that health plans
- 55:39Speaker 13: and providers and even employers are working together and different
- 55:42Speaker 13: physician specialties. Before this, we would think of cardiovascar disease
- 55:46Speaker 13: as being sort of separate from diabetes, and the cardio
- 55:50Speaker 13: cardiologists works separately from the undocrinologist. But now that we
- 55:54Speaker 13: start to think of the atology as well as the
- 55:56Speaker 13: treatment for all of these diseases is being oftentimes the
- 55:59Speaker 13: same thing, I think you're gonna see a reorientation of
- 56:03Speaker 13: of of how these doctors work together, and you're going
- 56:05Speaker 13: to see more centers of excellence forming along with those
- 56:09Speaker 13: collaborations with help plans and employers to make sure we're
- 56:12Speaker 13: targeting the right patients using the right data. I think
- 56:16Speaker 13: the second piece is I'm really excited about some of
- 56:19Speaker 13: the broader societal impacts here, you know, and I truly
- 56:24Speaker 13: hope and believe that that that by addressing cardio metabolic
- 56:28Speaker 13: disease and obesity, we see things like, you know, reduce
- 56:32Speaker 13: gas prices I'm sorry, I'm sorry, reduced gas utilization I've
- 56:35Speaker 13: you know, some of the airlines were projecting that because
- 56:38Speaker 13: the weight of the plane, you know, would would be lower,
- 56:41Speaker 13: that they wouldn't need to use as much gas and
- 56:43Speaker 13: a Walmart was rethinking, you know, what the demand for
- 56:46Speaker 13: their products would be. And so I think, to me,
- 56:49Speaker 13: that's just really exciting to watch of how this really
- 56:52Speaker 13: not just shapes our world within medicine, but also sort
- 56:56Speaker 13: of broader society.
- 56:57Speaker 3: As a whole. What about education?
- 57:01Speaker 7: You know, when I think of the pharmacist, my favorite
- 57:04Speaker 7: provider keep saying that, but I can't help it. I
- 57:08Speaker 7: think of the education. So safety comes to my number one.
- 57:13Speaker 7: I've been asked, you know, in elevators, in people that
- 57:19Speaker 7: are on my Facebook that say, what do you care
- 57:21Speaker 7: about pharmacists so much?
- 57:22Speaker 3: And what do they do?
- 57:23Speaker 7: And I said, you know, to sum up, the primary
- 57:27Speaker 7: reason for the existence of our existence of a pharmacist
- 57:30Speaker 7: is safety. It's patient safety, and with safety is education.
- 57:35Speaker 7: So what's needed, Mike, in your opinion, to ensure that
- 57:40Speaker 7: the appropriate use of GLP one drugs for optimal health
- 57:43Speaker 7: outcomes is established?
- 57:46Speaker 2: Time? Lots and lots of time, right, I mean, so,
- 57:52Speaker 2: as Julie said, we GLP once have been around for
- 57:55Speaker 2: a while. I think as an industry or you know,
- 57:57Speaker 2: healthcare is pretty comfortable with the side effect profile of
- 58:02Speaker 2: a g LP one. But keep in mind, these aren't
- 58:05Speaker 2: oral tablets, right, So this is this is a bit
- 58:08Speaker 2: more complex to a patient than just sort of take
- 58:11Speaker 2: one tablet by mouth every day. There is a whole
- 58:15Speaker 2: procedure that has to go on to be able to
- 58:17Speaker 2: inject this medicine appropriately. And so you know, pharmacists are
- 58:25Speaker 2: in a pretty tough position where, uh, you know, the
- 58:30Speaker 2: workload sometimes is just it's just too high for one
- 58:33Speaker 2: one pharmacist to handle at the pharmacy. So there needs
- 58:35Speaker 2: to be more time for the pharmacists to properly educate
- 58:38Speaker 2: patients on I would say, like the normal use of
- 58:41Speaker 2: a g LP one, you know, going back to something
- 58:46Speaker 2: that Todd, I think you had started the podcast by
- 58:48Speaker 2: saying that, uh, the sort of American lifestyle is to
- 58:52Speaker 2: just take this injection and it's going to fix all
- 58:54Speaker 2: my problems. That feels very reminiscent of insulin to me.
- 58:58Speaker 2: I think back to my grandparents who used to have
- 59:02Speaker 2: like an extra piece of cake after dinner and take
- 59:04Speaker 2: an extra shot of insulin, and their whole thought process was, well,
- 59:08Speaker 2: I can just inject extra insulin because you know, it's
- 59:11Speaker 2: going to save me from this. I think what's interesting
- 59:14Speaker 2: and Julie kind of talked about this with the expanding
- 59:17Speaker 2: indications of GLP ones is that this isn't just a hormone.
- 59:21Speaker 2: There there is like some type of mental component to
- 59:24Speaker 2: a GLP one too. And what I mean is, you know,
- 59:27Speaker 2: when you think about a GLP one being used for
- 59:30Speaker 2: something like you know, like a gambling addiction, for shopping
- 59:35Speaker 2: addiction or something like that, you know that has nothing
- 59:37Speaker 2: to do with your eating. But there's there's something going
- 59:40Speaker 2: on with the drugs and the sort of mental aspect
- 59:43Speaker 2: of it, and I feel like that is going to
- 59:47Speaker 2: be a bit different as we get into the future
- 59:51Speaker 2: of these drugs. Then, you know, when you compare it
- 59:54Speaker 2: to say insulin, where you know, there's already studied evidence
- 1:00:00Speaker 2: that the patients who take a GLP one and have
- 1:00:04Speaker 2: some type of supportive lifestyle change, whether it's a program
- 1:00:08Speaker 2: or you know, some type of support mechanism that goes
- 1:00:11Speaker 2: along with it, that they actually fare out better overall
- 1:00:14Speaker 2: than somebody who just takes the drug by itself. But
- 1:00:17Speaker 2: you know, I think the name of the game here
- 1:00:19Speaker 2: is to really get patients, allow patients to be on
- 1:00:22Speaker 2: this drug for long enough and safely enough so that
- 1:00:26Speaker 2: they can start to realize those lifestyle habits, and you know,
- 1:00:30Speaker 2: I think inevitably sort of losing weight makes you want
- 1:00:34Speaker 2: to be healthier, right, So it kind of it kind
- 1:00:37Speaker 2: of bodes well for the drug in and of itself
- 1:00:39Speaker 2: that if the patients just stay on it for long enough,
- 1:00:41Speaker 2: they you know, they should end up in a position
- 1:00:44Speaker 2: where they've decreased their weight, they potentially are not diabetic anymore,
- 1:00:49Speaker 2: their hypertension comes down to normal levels, and can eventually
- 1:00:53Speaker 2: get off the drug because they are now at this
- 1:00:55Speaker 2: sort of healthy baseline and want to remain in that position.
- 1:00:58Speaker 2: So I kind of see it as a opportunity to
- 1:01:01Speaker 2: like hit a reset button on patients who have lived
- 1:01:04Speaker 2: a pretty unhealthy lifestyle for you know, however, long.
- 1:01:09Speaker 7: So personal testimony and and it's time. It's exactly what
- 1:01:15Speaker 7: you said, Mike. We can do the BMI math, but
- 1:01:20Speaker 7: this is an at all. This is the obvious one.
- 1:01:23Speaker 7: I'm a five foot seven male, fifty two years old.
- 1:01:27Speaker 7: I was one hundred and eighty seven pounds. Doesn't take
- 1:01:30Speaker 7: a BMI calculator to say wow, I mean I was.
- 1:01:33Speaker 7: I was considered obese, and it was chubby and not
- 1:01:37Speaker 7: not doing well in My blood pressure was one thirty
- 1:01:41Speaker 7: five one thirty eight over. I can't remember what that
- 1:01:45Speaker 7: other number was, but it was definitely high. It needed
- 1:01:48Speaker 7: to be one twenty or lower. Right, So getting myself
- 1:01:52Speaker 7: on a phenillal effort.
- 1:01:54Speaker 3: I can't say it. Say it Mike of no effort friend.
- 1:01:58Speaker 7: Yeah, it kind of was like a cheat code for
- 1:02:01Speaker 7: a little while. But what I was doing is I
- 1:02:03Speaker 7: was adding in my exercise. I was adding in weightlifting.
- 1:02:06Speaker 7: I was getting back to that which this was like
- 1:02:08Speaker 7: a whole year process, because now today I'm one hundred
- 1:02:12Speaker 7: and sixty eight pounds. I don't take the medication anymore
- 1:02:15Speaker 7: because I didn't really like it. It made me feel
- 1:02:17Speaker 7: a little, a little edgy. I don't know how to
- 1:02:19Speaker 7: can Fener mean yeah, Bencher mean yeah, Okay, exactly the
- 1:02:24Speaker 7: non pharmacist here, But it felt made me feel edgy.
- 1:02:28Speaker 7: Even my fingertips were weird. But I mean, I take
- 1:02:31Speaker 7: it once in a while, wasn't it taking it every day?
- 1:02:32Speaker 7: It was kind of like I said, it was a
- 1:02:34Speaker 7: cheat code. But now that I got onto the exercise
- 1:02:37Speaker 7: four days a week, weightlifting three days a week, it's
- 1:02:40Speaker 7: become addictive to me. It's a new substance. But the
- 1:02:43Speaker 7: medication helped me get now I'm not even on the medication,
- 1:02:47Speaker 7: and now I'm I'm churning. I'm eating one point five
- 1:02:50Speaker 7: meals a day, tons of protein, tons of water. Didn't
- 1:02:53Speaker 7: even didn't drink water back in the day, you know,
- 1:02:55Speaker 7: a year ago even, And and I'm going to that
- 1:02:59Speaker 7: weight to get that one fifty level and get ripped
- 1:03:02Speaker 7: up finally and get back my swimming body since I
- 1:03:05Speaker 7: was a swimmer back in the day.
- 1:03:07Speaker 3: But it's that took a while. That was not.
- 1:03:10Speaker 7: A you know, fentermine and done. You know, it was
- 1:03:15Speaker 7: definitely wasn't it was. It was fun for the first
- 1:03:18Speaker 7: couple of days because it makes you feel hyper and
- 1:03:20Speaker 7: you work faster or something like that. But then and
- 1:03:24Speaker 7: then double using it, I guess you could call off label.
- 1:03:29Speaker 7: It was almost like a an attention difference for me,
- 1:03:33Speaker 7: and I started I started treating my work day different
- 1:03:38Speaker 7: based on the fact that I would celebrate more of
- 1:03:40Speaker 7: what I ate at the end of the day or
- 1:03:42Speaker 7: in the morning, depending how it was flip flopping. And
- 1:03:44Speaker 7: then I learned to actually change things up so now
- 1:03:47Speaker 7: it's not as hard for me.
- 1:03:48Speaker 3: And I'm a nut guy.
- 1:03:49Speaker 7: I take a handful of almonds or something and nonsalted,
- 1:03:53Speaker 7: and it's like, I got a whole way of life now,
- 1:03:57Speaker 7: But that didn't I have to say to the people
- 1:03:59Speaker 7: listening out there that if you're dealing with obesity, get
- 1:04:02Speaker 7: ready for a journey that becomes just part of your life.
- 1:04:06Speaker 7: And now I don't I can live the way that
- 1:04:08Speaker 7: I am right now that I've gotten used to the
- 1:04:09Speaker 7: way that I eat.
- 1:04:10Speaker 3: Now and what I eat now and what I'm hungry for.
- 1:04:12Speaker 7: And now it's a lot more less processed foods and
- 1:04:15Speaker 7: it's a lot easier to cook. And but that whole
- 1:04:18Speaker 7: element that took a while to lay down, that structure,
- 1:04:21Speaker 7: and now it's now, it's easy.
- 1:04:23Speaker 3: It's it wasn't easy. It was very very hard to change.
- 1:04:27Speaker 7: Alcohol intake was, you know, changed, Exercise was definitely changed.
- 1:04:33Speaker 7: But I think that's the concept of what you were
- 1:04:35Speaker 7: talking about, Julie in the in the start of the show.
- 1:04:40Speaker 3: Absolutely well.
- 1:04:41Speaker 13: And I would add, since you know you brought up BMI,
- 1:04:44Speaker 13: I think everyone in healthcare would agree that BMI is
- 1:04:47Speaker 13: is not a great marker of cardiom metabolic health. It's
- 1:04:50Speaker 13: a it's a crude and somewhat helpful population health management tool,
- 1:04:54Speaker 13: but it's terrible at the individual level to help assess
- 1:04:59Speaker 13: risks of downstream cardiovascular or cardio metabolic disease, just as
- 1:05:05Speaker 13: by way of comparison. You know, I've always had a
- 1:05:07Speaker 13: BMI in the healthy range, but I have family history
- 1:05:10Speaker 13: of cardiovascular disease and now take medication for both blood
- 1:05:14Speaker 13: pressure and as well as high cholesterol, and for me
- 1:05:19Speaker 13: that's just genetic and so we really need to again.
- 1:05:23Speaker 13: I think that brings it back to sort of looking
- 1:05:25Speaker 13: for other tools to identify to identify patients who are
- 1:05:30Speaker 13: going to benefit, such as lab values and biomarkers. I
- 1:05:33Speaker 13: think that's really going to be the future of assessing
- 1:05:36Speaker 13: and treating cardio metabolic disease instead of some of these
- 1:05:41Speaker 13: more crude tools like BMI.
- 1:05:45Speaker 2: And so taught up. I mean, first of all, congratulations,
- 1:05:48Speaker 2: because that's a huge accomplishment for you to no seriously,
- 1:05:52Speaker 2: I mean, I know, I'm since everybody else did, I
- 1:05:54Speaker 2: might as well go ahead and do it too. My
- 1:05:56Speaker 2: BMI is a thirty two, so you know, by the
- 1:05:59Speaker 2: sort of scale by the book there, I'm considered obese,
- 1:06:02Speaker 2: but I'm a six six' one male And i'm right
- 1:06:05Speaker 2: now at like two hundred and thirty five. POUNDS i
- 1:06:08Speaker 2: was at two hundred and seventy two years, ago SO
- 1:06:11Speaker 2: i am right there with, You. Todd it's been a long.
- 1:06:13Speaker 2: Journey it's taken a lot of effort and, time AND
- 1:06:17Speaker 2: i think on top of, time there's also an education,
- 1:06:20Speaker 2: component AND i Think julie was kind of talking about
- 1:06:22Speaker 2: this with you, know the center Of excellence idea and
- 1:06:26Speaker 2: bringing in multi, multi multiple disciplines to really like all
- 1:06:31Speaker 2: together treat the. PATIENT i, mean so much of this
- 1:06:34Speaker 2: is it's not just the, drug it's the eating, habits
- 1:06:39Speaker 2: it's the exercise. Habits and from a pharmacist, PERSPECTIVE i,
- 1:06:43Speaker 2: Mean i'm an exercise, nut so it's easy for me
- 1:06:46Speaker 2: to be able to educate somebody on, like you, know
- 1:06:49Speaker 2: what percentage of your macro should you be eating that
- 1:06:51Speaker 2: that relates to protein and fats and carbohydrates and what
- 1:06:54Speaker 2: are processed. Carbohydrates all that stuff is not typically taught
- 1:06:59Speaker 2: in pharmacy. School that stuff That i've had to go
- 1:07:01Speaker 2: out and learn on my. Own but, AGAIN i mean
- 1:07:04Speaker 2: that takes time just getting that education under your belt
- 1:07:07Speaker 2: to know what SHOULD i be eating to help better
- 1:07:10Speaker 2: benefit my healthcare journey with the start of This goop,
- 1:07:13Speaker 2: one it takes time and.
- 1:07:14Speaker 7: Effort absolutely it. Does it's a dial in and now
- 1:07:20Speaker 7: it was one sixteen. OVER i can never know my bottom,
- 1:07:23Speaker 7: number but it's definitely. Dropped my cholesterol has also, Changed,
- 1:07:27Speaker 7: Julie so my family is also candidate for my dad's
- 1:07:31Speaker 7: on a cholesterol. Medication i'm not, yet BUT i was hovering,
- 1:07:35Speaker 7: there and so it's it's not it's not. Easy it's
- 1:07:40Speaker 7: it's absolutely not. EASY i think of getting you both
- 1:07:44Speaker 7: back at some point so we can continue to kind
- 1:07:46Speaker 7: of talk about this Because i'd like to talk about
- 1:07:50Speaker 7: the different. Stages i'd like to talk about. Pediatrics i'd
- 1:07:54Speaker 7: like to talk about kind of your your teenage, years
- 1:07:58Speaker 7: middle age, years and my, annidacy the geriatric. Years so
- 1:08:02Speaker 7: there's a lot of elements to actually start splitting the hairs.
- 1:08:06Speaker 7: Here so this has Been this has been an awesome
- 1:08:08Speaker 7: conversation with both of.
- 1:08:09Speaker 3: You very much appreciate.
- 1:08:10Speaker 7: It before you, GO i wanted to pitch to, You,
- 1:08:13Speaker 7: julie just for listener's, sake how do you see the
- 1:08:16Speaker 7: introduction of NEW glp one. DRUGS i love the topic of.
- 1:08:20Speaker 7: Biosimilars we used to talk to one of our, Clients
- 1:08:23Speaker 7: Cardinal health about their, biosimilars you, know, Initiatives but how's
- 1:08:28Speaker 7: that going to impact the future of patient act access and.
- 1:08:31Speaker 13: Affordability SO i think we have a very robust pipeline
- 1:08:36Speaker 13: OF glp one, drugs including oral, agents some of which
- 1:08:39Speaker 13: are available. TODAY i think while that might introduce some,
- 1:08:44Speaker 13: competition the just explosion and potential INDICATIONS i think will
- 1:08:50Speaker 13: kind of counteract some of those downward price. Pressures and so,
- 1:08:55Speaker 13: UNFORTUNATELY i DON'T i don't think that there's going to
- 1:08:57Speaker 13: be a magic bullet to bring down the cost of
- 1:09:00Speaker 13: these drugs anytime. Soon if there, is If i'm, wrong that's,
- 1:09:02Speaker 13: great but just the the the there's just so many
- 1:09:06Speaker 13: different applications and ways THAT i think pharmaceutical companies can
- 1:09:10Speaker 13: can maintain exclusivity and niche of the market THAT i
- 1:09:14Speaker 13: think prices might continue to stay high for some. Time
- 1:09:17Speaker 13: we should also talk, about you, know some of the
- 1:09:20Speaker 13: other drugs you, know related in the pipeline that are
- 1:09:24Speaker 13: that perhaps you, know help patients avoid a liver transplant
- 1:09:28Speaker 13: or treat other end stages. Everything all of these drugs
- 1:09:31Speaker 13: have extremely high price, tags AND i, think UNFORTUNATELY glp
- 1:09:36Speaker 13: ones might just be the tip of the. Iceberg SO
- 1:09:39Speaker 13: i WISH i had better news for, You, ton but
- 1:09:42Speaker 13: BUT i think this is a problem that will unfortunately
- 1:09:45Speaker 13: be kind of working to solve for quite some.
- 1:09:47Speaker 7: Time, mike you have to promise to come back to
- 1:09:51Speaker 7: twerus at some time and let's talk.
- 1:09:54Speaker 3: Shop i'll have, many many a subjects to throw at.
- 1:09:57Speaker 2: You love, it MISS i will be back on whenever
- 1:10:01Speaker 2: you want me.
- 1:10:01Speaker 3: To you've been listening to This week In.
- 1:10:04Speaker 7: Pharmacy we've been talking with Doctor Julie schultz and Doctor Mike.
- 1:10:10Speaker 7: DeVito this has been a wonderful. DISCUSSION i want to
- 1:10:14Speaker 7: thank you both for being my guest today and This
- 1:10:16Speaker 7: week In.
- 1:10:17Speaker 3: Pharmacy thank You.
- 1:10:18Speaker 2: Tod, yeah thank You.
- 1:10:20Speaker 7: Todd in today's fast paced pharmaceutical, landscape having a reliable
- 1:10:30Speaker 7: partner is crucial for the success of independent and specialty.
- 1:10:34Speaker 7: Pharmacies that's WHERE fh Two pharma comes.
- 1:10:37Speaker 14: In founded in twenty eighteen by industry, LEADERS fh Two
- 1:10:41Speaker 14: pharma recognized the need for virtual pharmaceutical companies specializing in.
- 1:10:46Speaker 14: Generics their mission to ensure that the independent and specialty
- 1:10:50Speaker 14: pharmacies have consistent access to unique dosage formulations of generic.
- 1:10:54Speaker 7: Medications what SETS fh Two pharma part every product is
- 1:11:00Speaker 7: proudly manufactured in The United, states ensuring top nuch quality and.
- 1:11:05Speaker 7: Reliability this commitment means pharmacies can depend on a predictable product,
- 1:11:10Speaker 7: supply even amidst market.
- 1:11:13Speaker 3: Fluctuations but it's not just about.
- 1:11:15Speaker 14: SUPPLY fh Two pharma's unique dosage formulations are designed to
- 1:11:20Speaker 14: meet specific patient, needs allowing for more flexible prescribing and
- 1:11:24Speaker 14: better patient. Outcomes, plus their focus on specialty and independent
- 1:11:27Speaker 14: pharmacies means they're dedicated to improving your profit.
- 1:11:31Speaker 7: Margins imagine reducing margin loss prescriptions by offering unique dosages
- 1:11:37Speaker 7: at improve. Margins WITH fh Two, pharma this isn't just a,
- 1:11:41Speaker 7: possibility it's a.
- 1:11:42Speaker 14: Reality ready to enhance your pharmacies. Offerings CONTACT fh Two
- 1:11:46Speaker 14: pharma today to discuss, partnerships stalking their, products or other
- 1:11:50Speaker 14: business related.
- 1:11:51Speaker 7: INQUIRIES fh Two pharma your trusted partner for unique dosage
- 1:11:55Speaker 7: formulations of, generics ensuring your pharmacy thrives in today competitive.
- 1:12:00Speaker 7: Market learn more AT fh two pharma dot. Net that's
- 1:12:05Speaker 7: F h two pharma dot. Net tell them you learned
- 1:12:08Speaker 7: about F h Two pharma on The Pharmacy Podcast network